Conflict of interest: Prof. Sievert has received study honoraries, travel expenses and/or consulting fees from all companies manufacturing devices subject to discussion in this manuscript. Drs. Bertog, Majunke, Reiffenstein, Renkhoff, Lehn, and Wunderlich and Johannes Masseli, Lukas Stanczak and Kira Blankenbach have no conflicts of interest.
Pediatric and Congenital Heart Disease
Transcatheter closure of multiple interatrial communications
Article first published online: 20 AUG 2012
Copyright © 2012 Wiley Periodicals, Inc.
Catheterization and Cardiovascular Interventions
Volume 81, Issue 5, pages 825–836, April 2013
How to Cite
Masseli, J., Bertog, S., Stanczak, L., Blankenbach, K., Majunke, N., Reiffenstein, I., Renkhoff, K., Lehn, K., Wunderlich, N. and Sievert, H. (2013), Transcatheter closure of multiple interatrial communications. Cathet. Cardiovasc. Intervent., 81: 825–836. doi: 10.1002/ccd.24329
- Issue published online: 21 MAR 2013
- Article first published online: 20 AUG 2012
- Manuscript Accepted: 7 JAN 2012
- Manuscript Received: 14 MAY 2011
- multiple atrial septal defects;
- patent foramen ovale;
- atrial septal defect;
- device closure
We sought to examine acute and midterm results of closure of multiple interatrial communications with staged device deployment and to review the relevant literature.
Information about percutaneous methods of closure for multiple defects is limited.
We treated 148 patients with multiple defects. Of these, 88 had a relevant left to right shunt (“LRS”), 52 had a presumed paradoxical embolism (“PPE”), five had both (LRS and PPE), and one patient, respectively, had migraine, decompression sickness, and a right to left shunt. After implantation of the first device, closure of additional septal defects was attempted only if indicated clinically.
Ninety-four patients received a single device and 53 more than one. In four patients, surgical defect closure followed. At the end of follow-up (FU; mean 4.5 ± 3.4 years), complete closure of all defects occurred in 67.6% (62.1% for LRS, 76.5% for PPE). Clinical success (small or trivial residual shunt) was achieved in 86.9% (83.9% for LRS, 90.2% for PPE). Complications included pericardial effusions in 2.7%, recurrent thromboembolic events in 4.8%, and new onset of atrial fibrillation in 10.1%. In a significant number of patients with multiple defects, after single device implantation, the likelihood of complete closure increased with FU time (26% complete closure at 1 month vs. 78% at 24 months).
Percutaneous closure of multiple interatrial communications is feasible and safe. Importantly, many residual defects close without further intervention at FU. Therefore, staged device delivery is an alternative to simultaneous device implantation, possibly requiring fewer and smaller second devices. © 2012 Wiley Periodicals, Inc.